Fig. 1From: Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trialKaplan–Meier plot of TTF on-treatment CVAESI. CVAESI, cardiovascular adverse event of special interest; FF, fluticasone furoate; TTF, time to first; UMEC, umeclidinium; VI, vilanterolBack to article page